Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Part of paid clinical trials in Fairfax, Virginia.

Sponsor
Nuvectis Pharma, Inc.
Study ID
NCT07784959
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • ALK Positive
  • ALK Positive Non-small Cell Lung Cancer
  • ALK+ Non-Small-Cell Lung Carcinoma
  • NSCLC

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • NXP900 — DRUG
    NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
  • Lorlatinib — DRUG
    Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Study Details

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Key Dates

First listed
Aug 25, 2026
Start date
Aug 17, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Exploration
    Escalating doses of NXP900 given with lorlatinib

Primary Outcome Measure

Number of patients with treatment related adverse events and/or clinical laboratory abnormalities [ Time Frame: Up to 30 days post treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NEXT VirginiaFairfaxVirginia22031-

Find similar trials in Fairfax, VA

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials
By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
NEXT Virginia· Fairfax, VA

Related Studies